View profile

FarmaKology-New Genomics Technology Could Power Gene Therapy in Oncology

Revue
 
 

FarmaKology

April 8 · Issue #102 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+15K Subscribers )!

FarmaKology-New Genomics Technology Could Power Gene Therapy in Oncology
FarmaKology-New Genomics Technology Could Power Gene Therapy in Oncology
Novo Banking
Novo Banking
Today's Company
Panavance Therapeutics Inc.
Panavance Therapeutics Inc.
Panavance Therapeutics Inc.
Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, in order to advance the development of GP-2250, a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them.With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world. To date, our therapeutic has demonstrated substantial efficacy and safety in extensive preclinical studies, and its early clinical results have been encouraging. Panavance has developed a clear pathway to US registration of GP-2250 for pancreatic cancer.
News
 Pfizer Inc. and ReViral Ltd. announced today that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).
The European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.
Jazz Pharmaceuticals plc and Werewolf Therapeutics, Inc. today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf’s investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.
Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and the nonprofit scientific research organization IAVI today announced a new collaboration to employ mRNA technology to meet the challenge of a range of global health threats. These diseases - HIV/AIDS, tuberculosis (TB), antimicrobial-resistant enteric infections, and COVID-19 - are estimated to have caused at least 95 million new infections and more than 4 million deaths in 2020 alone. The collaboration combines the power of Moderna’s mRNA platform and IAVI’s expertise in discovery and product development to advance vaccines and antibodies designed to be globally accessible, especially in low-income countries where the targeted diseases have high incidence and prevalence.
Research & Study
Podcast
Stream episode Drug Manufacturing Technology by Drug Solutions Podcast podcast | Listen online for free on SoundCloud
Job Opportunities
Upcoming Webinar & Event
Video
Big Pharma does not want you to know about Health
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue